Eli Lilly & Company http://www.alacrastore.com/company-snapshot/Eli_Lilly_Company-1009952 Wednesday, October 08, 2008 4:09:12 AM 1009952 Eli Lilly & Company en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/newstex/PRN-0004-28604098newstex/PRN-0004-28604098xml London, Oct. #, #### (PR Newswire UK Disclose delivered by Newstex) -- Date: October #, #### For Release: Immediately Refer to: (###) ###-#### - Mark Taylor ...040000000400200004002006040160000401604804016018070000000700300007003001070140000701401210/8/2008 3:21:02 AM180000001800800018004000190000001900100019001014PR Newswire UK DisclosePRN-0004-28604098LILLY ELI & COLLYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-28596331newstex/PRN-0005-28596331xml INDIANAPOLIS, Oct. #, #### (PRNewswire-FirstCall delivered by Newstex) -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of #### on Thursday, October ##, ####. Lilly will also conduct a...040000000400200004002006040160000401601804016048070000000700300007003001070140000701401210/7/2008 5:20:59 PM180000001800400018008000PR Newswire USPRN-0005-28596331LILLY ELI & COLLYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/HUG-0001-28590532newstex/HUG-0001-28590532xml Oct. #, #### (Hugin AS delivered by Newstex) -- Summit Corporation plc ("Summit plc" or "the Company") SUMMIT PLC ENTERS INTO A CO-DEVELOPMENT AGREEMENT WITH THE LILLY TB DRUG DISCOVERY INITIATIVE FOR TUBERCULOSIS PROGRAMME Oxford,...0700000007001000050000000500200004000000040020000400200604006000040060050401600004016013070030000700300107014000070140121100000011014000110140021100200011002001130000001300200013002005130100001301000510/7/2008 12:20:57 PM1800000018022000180020001801500018020000Hugin ASHUG-0001-28590532LILLY ELI & COLLYNewsNewstexhttp://www.alacrastore.com/storecontent/moodys/PR_164306_808606410moodys/PR_164306_808606410htmlGlobal Credit Research Rating Action # OCT #### Rating Action: Eli Lilly Services, Inc. Moody's reviews Eli Lilly's Aa# for possible downgrade Approximately $#.# Billion of Outstanding Debt Affected New York, October ##, #### -- Moody's...10/7/2008 4:37:09 AMhtmlEli Lilly Services, Inc.Eli Lilly and CompanyLilly Savings Plan Master Trust CEli Lilly and Company; Eli Lilly Services, Inc.; ...80860641044720020130150.0000NewsRating ActionPR_164306_808606410Credit & Investment ResearchMoody's Global Credit Researchhttp://www.alacrastore.com/storecontent/fitch/442536_pr_framefitch/442536_pr_framehtmlFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.Eli Lilly & Company8065623610/6/2008 6:28:00 PM0103000001031700010317030104000085Press ReleaseLLY442536_pr_frameCredit & Investment ResearchFitch Researchhttp://www.alacrastore.com/storecontent/spcred/675141spcred/675141normThe latest News from S&Pglobalstructured10/6/2008 10:31:05 AM100News675141United StatesPharmaceuticalsEmerging MarketsEurope, Middle East, AfricaLatin AmericaUnited StatesGlobal IssuersStructured FinanceCorporationsAsset-Backed SecuritiesHealth CareConsumer ProductsNewsNEW YORK (Standard&Poor's) Oct. 6, 2008--Standard&Poor's Ratings Services said today that its ratings and outlook on Eli Lilly&Co. (AA/Stable/A-1+) are not affected by the company's agreement to purchase Imclone Systems Inc. (not rated) for about $6.5 billion in cash. We estimate that financial leverage will remain well within the guideline of less than 1.5x adjusted debt to EBITDA and funds from operations to debt greater than 60% for an issuer to be considered to have a minimal financial risk profile. Indeed, we estimate that debt to EBTIDA will peak at only slightly more than 1.0x for this proposal. However, Lilly would benefit from improved product diversity. Imclone's sole marketed product is Erbitux, a monoclonalUSA53245753245M53245N53245R53245P53245Q53245S35202010 352020 3520 35Eli Lilly&Co.101358EMERGINGEUROMIDAFRLATAMERICAUSALLYNEWSGLOBISSSTRUCCORPABSHealthConsumerCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-28563633newstex/PRN-0005-28563633xml INDIANAPOLIS and NEW YORK, Oct. #, #### (PRNewswire-FirstCall delivered by Newstex) -- Eli Lilly and Company (NYSE: LLY) and ImClone Systems Inc. (Nasdaq: IMCL) today announced that the boards of directors of both companies have approved...0700000007005000070130000400000004002000040020060400200104016000040160050401601904016018040160010400600004006005070140000701400807014012070140190701400707014015070140090700300007003001070030040700100007001004020000000200200002002006130000001301000013010005130010001300100206000000060050000600500310/6/2008 7:21:39 AM180000001801600018022000180230001900000019001000PR Newswire USPRN-0005-28563633IMCLONE SYSTEMS INCLILLY ELI & COJOHN C LECHLEITERJohn H JohnsonIMCLLLYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MCOM-0004-28563466newstex/MCOM-0004-28563466xml Oct. #, #### (M# Communications Ltd. delivered by Newstex) -- Eli Lilly and Company (NYSE: LLY), a provider of first-in-class and best-in-class pharmaceutical products, announced on # October that the company has signed a collaboration...040000000400200004002006070000000700300007003001070140000701401210/6/2008 7:21:38 AM1800000018022000M2 EquityBitesMCOM-0004-28563466LILLY ELI & COLLYNewsNewstexhttp://www.alacrastore.com/storecontent/moodys/PBC_89391moodys/PBC_89391pdf...Eli Lilly improved governance significan tly following difficulties faced by th e company in the early ####s, and we have confidence in the general governanc e structure. The board appears to have good medical/scientific skills, and to be strongly engaged on issues related to R&D and the pr oduct pipeline, as well as crit ical risk and control issues, such as the considerable reputational risk issues of ph armaceutical companies. This includes significant board involvement in oversight of quality pr ocesses following the #### FDA "warni ng letter" on manufacturing quality control concerns. While we believe th e board could be strength ened with additional specific experience in accounting/corporate finance work, and arguably on the manufacturing si de, the overall mix of director backgrounds appears good. There was a change on the direction of executive pay incentives following the board compensation committee's decision in #### to aban don the economic-value-added approach... 10/4/2008 8:29:49 PMpdfEli Lilly and CompanyEli Lilly and Company447200300.00AnalysisCorporate Governance AssmtPBC_89391Credit & Investment ResearchMoody's Global Credit ResearchUS - Eli Lilly & Co was rumored to be planning to launch a challenging offer to acquire all the outstanding common stock of ImClone Systems Inc (IS), a biotechnology company. Previously, Bristol-Myers Squibb Co planned to launch a hostile tender offer to acquire the remaining ##% interest, which it did not already own in IS.10/3/2008 1:32:26 PM53245745245W53245745245WEli Lilly & CoImClone Systems IncEli Lilly & CoImClone Systems Inchttp://www.alacrastore.com/storecontent/Thomson_M%26A/Eli_Lilly_Co_is_rumored_to_be_planning_to_acquire_ImClone_Systems_Inc-2016919020sdc/20169190202016919020Copyright © 2008, Thomson Financial, All Rights ReservedNew YorkDrugsUnited StatesPharmaceutical preparations2834INIndianaPublicLLY2048:Prepared animal feeds, except for dogs and cats2819:Industrial inorganic chemicals, nec2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations3841:Surgical and medical instruments and apparatus3844:X-Ray apparatus & tubes & other irradiation equip.5122:Drugs, drug proprietaries, and druggists' sundries8731:Commercial physical and biological research8741:Management services2048:Prepared animal feeds, except for dogs and cats2819:Industrial inorganic chemicals, nec2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations3841:Surgical and medical instruments and apparatus3844:X-Ray apparatus & tubes & other irradiation equip.5122:Drugs, drug proprietaries, and druggists' sundries8731:Commercial physical and biological research8741:Management servicesNasdaqDrugsUnited StatesBiological products, except diagnostic substances2836NYNew YorkPublicIMCL3547001Mnfr,whl pharmBiotech coNot ApplicableCommon Stock175791001Oct 3 20089.35000935.61100192.94500193.54300318.5770086.20600193.69100-100.90400809.632000.530000.74100159.81800-0.71000-62.00900-19.70700628.06000600.000001721.43300US30 Jun 080.000003.480003803.800000.0000019734.4000027752.00000U.S. Dollar30 Jun 0831 Dec 0731 Dec 0631 Dec 0531 Dec 0431 Dec 031.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.0000023.0000024.0000025.0000026.0000027.0000028.0000029.0000030.0000031.00000Eli Lilly & Co, headquarteredin Indianapolis, Indiana,manufactures and wholesalespharmaceuticals, medicalinstruments, diagnostic andanimal health products. Thepharmaceutical productsinclude: Neuroscience,Endocrine, Anti-infective,Cardiovascular agents,Oncology and Animal Health.The company specializes inresearch and development,production and marketing ofproducts for the treatment ofdiabetes worldwide, such asinsulin and insulin deliverydevices. The company providesresearch and developmentfacilities in nine countriesand conducts clinical trials.The company's patents includeZyprexa, Prozac, Permax,Darvon, Humulin, Evista,Humalog, Actos, Humatrope,Ceclor, Vancocin, Keflex,Nebcin , Lorabid, Gemzar,Tylan, Rumensin, Micotil,Surmax, Coban, ReoPro, Xigris,Dobutrex and Axid. The companywas founded on May 10, 1876.Eli Lilly & Co, headquartered in Indianapolis, Indiana,manufactures and wholesales pharmaceuticals, medicalinstruments, diagnostic and animal health products. Thepharmaceutical products include: Neuroscience, Endocrine,Anti-infective, Cardiovascular agents, Oncology and AnimalHealth. The company specializes in research and development,production and marketing of products for the treatment ofdiabetes worldwide, such as insulin and insulin deliverydevices. The company provides research and developmentfacilities in nine countries and conducts clinical trials.The company's patents include Zyprexa, Prozac, Permax,Darvon, Humulin, Evista, Humalog, Actos, Humatrope, Ceclor,Vancocin, Keflex, Nebcin , Lorabid, Gemzar, Tylan, Rumensin,Micotil, Surmax, Coban, ReoPro, Xigris, Dobutrex and Axid.The company was founded on May 10, 1876.Eli Lilly & Co, headquartered in Indianapolis, Indiana, manufactures and wholesales pharmaceuticals, medical instruments, diagnostic and animal health products. The pharmaceutical products include: Neuroscience, Endocrine, Anti-infective, Cardiovascular agents, Oncology and Animal Health. The company specializes in research and development, production and marketing of products for the treatment of diabetes worldwide, such as insulin and insulin delivery devices. The company provides research and development facilities in nine countries and conducts clinical trials. The company's patents include Zyprexa, Prozac, Permax, Darvon, Humulin, Evista, Humalog, Actos, Humatrope, Ceclor, Vancocin, Keflex, Nebcin , Lorabid, Gemzar, Tylan, Rumensin, Micotil, Surmax, Coban, ReoPro, Xigris, Dobutrex and Axid. The company was founded on May 10, 1876.1.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.00000ImClone Systems Inc is abiotechnology companydeveloping and commercializingnovel therapeutic products inthe field of oncology marketedunder the ERBITUX brand,operating out of theirheadquarters in New York, NewYork, and their campus inBranchburg, New Jersey. TheBranchburg facility is home tothe manufacturing, productdevelopment, finance,clinical, regulatory andquality assurance andcommercial operationsdepartments. The company wasfounded in 1984.ImClone Systems Inc is a biotechnology company developingand commercializing novel therapeutic products in the fieldof oncology marketed under the ERBITUX brand, operating outof their headquarters in New York, New York, and theircampus in Branchburg, New Jersey. The Branchburg facility ishome to the manufacturing, product development, finance,clinical, regulatory and quality assurance and commercialoperations departments. The company was founded in 1984.ImClone Systems Inc is a biotechnology company developing and commercializing novel therapeutic products in the field of oncology marketed under the ERBITUX brand, operating out of their headquarters in New York, New York, and their campus in Branchburg, New Jersey. The Branchburg facility is home to the manufacturing, product development, finance, clinical, regulatory and quality assurance and commercial operations departments. The company was founded in 1984.0.000000.000000.0000087.00000N01 Oct 08Wed, 01 Oct 2008 00:00:00 ESTDate Announced: 10/01/2008Date Effective:MergerNot Appl.Pending0.000000.000000.000000.000000.000000.00000Price/Share0.0000000.000000.0000000.000000.000000.000000.000000.000000.0000000.00000N0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000006.893000.00000100.000000.000000.000000.000000.000000.000000.000000.000000.0000053334.3320062.4000063.9500064.4500049.837000.000000.000000.00000-32.513000.000000.000005606.99300809.6320076.218000.00000-32.167000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.00000US - Eli Lilly & Co wasrumored to be planning tolaunch a challenging offer toacquire all the outstandingcommon stock of ImCloneSystems Inc (IS), abiotechnology company.Previously, Bristol-MyersSquibb Co planned to launch ahostile tender offer toacquire the remaining 83%interest, which it did notalready own in IS.US - Eli Lilly & Co was rumored to be planning to launch a challenging offer to acquire all the outstanding common stock of ImClone Systems Inc (IS), a biotechnology company. Previously, Bristol-Myers Squibb Co planned to launch a hostile tender offer to acquire the remaining 83% interest, which it did not already own in IS.US - Eli Lilly & Co was rumored to be planning to launch a challenging offer to acquireall the outstanding common stock of ImClone Systems Inc (IS), a biotechnology company.Previously, Bristol-Myers Squibb Co planned to launch a hostile tender offer to acquirethe remaining 83% interest, which it did not already own in IS.US - Eli Lilly & Co was rumored to be planning to launch a challenging offer to acquire all the outstanding common stock of ImClone Systems Inc (IS), a biotechnology company. Previously, Bristol-MyersSquibb Co planned to launch a hostile tender offer to acquire the remaining 83% interest, which it did not already own in IS.US - Eli Lilly & Co was rumored to be planning to launch a challenging offer to acquire all the outstanding common stock of ImCloneSystems Inc (IS), a biotechnology company. Previously, Bristol-Myers Squibb Co planned to launch a hostile tender offer to acquire theremaining 83% interest, which it did not already own in IS.Rumor14738.000003803.8000019734.4000027752.000009.35000192.94500193.54300318.5770086.20600193.69100-100.90400809.63200159.818000.460004.110001.010001.33000-1.52000-0.71000809.63200783.78900759.64900252.40400178.83800-270.5930039.79900370.6740086.49600113.65300-112.50200-62.0090095.29100320.3200088.07400131.01400-112.01100-19.70700590.83300677.84700383.67300388.6900080.83000628.060001721.433001687.216001715.803001343.415001434.77600381.59500Status:RumorUS-999.00000np0.00000-999.00000np4.016000.000000.0000024.0940064.42700809.6320012.0680045.008000.000000.000000.000002836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations3547001New YorkUnited States2834IndianaPublicLLY2836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations175791001NasdaqUnited States2836New YorkPublicIMCL0.000000.000000.000000.00000Deal InformationTF Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/newstex/PRN-0004-28524676newstex/PRN-0004-28524676xml London, Oct. #, #### (PR Newswire UK Disclose delivered by Newstex) -- Date: October #, #### For Release: Immediately Refer to: Mark E. Taylor (###) ###-#### (Lilly) Daniel...07000000070050000400000004002000040020060700300007003001070140000701401207014008070010000700100413000000130100001301000510/3/2008 10:19:42 AM1800000018022000190000001900100019001014PR Newswire UK DisclosePRN-0004-28524676LILLY ELI & COLLYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-28523567newstex/PRN-0005-28523567xml INDIANAPOLIS, Ind. and LAWRENCE, Kan., Oct. #, #### (PRNewswire-FirstCall delivered by Newstex) -- Eli Lilly and Company (NYSE: LLY) and privately-held Deciphera Pharmaceuticals, LLC today announced that the two companies have entered...07000000070050000400000004002000040020060700300007003001070140000701401207014008070010000700100413000000130100001301000510/3/2008 9:21:42 AM1800000018022000190000001900100019001014PR Newswire USPRN-0005-28523567LILLY ELI & COLLYNewsNewstexhttp://www.alacrastore.com/storecontent/fitch/440616_pr_framefitch/440616_pr_framehtmlFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.Eli Lilly & Company8065623610/1/2008 2:15:00 PM0103000001031700010317030104000085Press ReleaseLLY440616_pr_frameCredit & Investment ResearchFitch Researchhttp://www.alacrastore.com/storecontent/newstex/BW-0001-28483829newstex/BW-0001-28483829xml Oct. #, #### (Business Wire) -- Fitch Ratings has affirmed Eli Lilly and Co.'s (Eli Lilly) ratings as follows: --Issuer Default Rating (IDR) 'AA'; --Bank loan 'AA'; --Senior unsecured debt 'AA'; --Short-term IDR 'F#+'. The Rating...04000000040090000400900104002000040020060401600004016031070000000700300007003001070140000701401202000000020020000200200810/1/2008 11:23:22 AM1800000018024000180090001801800018020000Business WireBW-0001-28483829LILLY ELI & COLLYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-28299723newstex/PRN-0005-28299723xml SAN DIEGO, Sep. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders,...040000000401600007000000070050000400200004002006070150000701500307014000070140120700100007001007070030000700300113000000130010001300100213010000130100059/25/2008 9:27:13 AM1800000018007000PR Newswire USPRN-0005-28299723AMYLIN PHARMACEUTICALS INCENTEROMEDICS INCLILLY ELI & COAMLNETRMLLYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-28233339newstex/PRN-0005-28233339xml GENEVA and NEW YORK, Sep. ##, #### (PRNewswire delivered by Newstex) -- The International Council of Nurses (ICN) and Eli Lilly and Company (Lilly) announced today a dramatic scale-up in their partnership to support nurses in the global...04000000040020000400200604016000040160130700000007014000070140150701401207003000070030019/22/2008 11:21:33 AM1800000018015000180220001900000019002000190020011900200419002013PR Newswire USPRN-0005-28233339LILLY ELI & COBryce D CarmineLLYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-28230331newstex/PRN-0005-28230331xml Sep. ##, #### (PR Newswire delivered by Newstex) -- Toronto Stock Exchange Symbol: MS - US$## million received based on the positive review of interim analysis for international pivotal multiple sclerosis trial -EDMONTON, Sept....0700000007005000040000000400200004002006070140000701401207003000070030019/22/2008 9:25:30 AM1800000018022000PR Newswire USPRN-0005-28230331BIOMS MEDICAL CORPLILLY ELI & COLLYMSNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-28137361newstex/PRN-0005-28137361xml INDIANAPOLIS, Sep. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Eli Lilly and Company (NYSE: LLY) today announced that the company's board of directors has appointed John C. Lechleiter, Ph.D., chairman of the board effective...0400000004018000040170000900000009015000110000001100600004002000040020060401600004016008040160470401600207000000070140000701401207003000070030011300000013010000130100059/18/2008 9:26:40 AM1800000018007000190000001900100019001014PR Newswire USPRN-0005-28137361LILLY ELI & COJOHN C LECHLEITERKAREN N HORNSIDNEY TAURELLLYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0004-28138335newstex/PRN-0004-28138335xml London, Sep. ##, #### (PR Newswire UK Disclose delivered by Newstex) -- Date: September ##, #### For Release: Immediately Refer to: (###) ###-#### - Mark E. Taylor (###) ###-####...0400000004018000040170000900000009015000110000001100600004002000040020060401600004016008040160470401600207000000070030000700300107014000070140121300000013010000130100059/18/2008 9:26:39 AM1800000018007000180200001900000019001000190010141900200019002007PR Newswire UK DisclosePRN-0004-28138335LILLY ELI & COJOHN C LECHLEITERKAREN N HORNSIDNEY TAURELLLYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-28071728newstex/BW-0001-28071728xml Sep. ##, #### (Business Wire) -- Research and Markets (http://www.researchandmarkets.com/research/#aee#f/eli_lilly_and_comp) has announced the addition of the "Eli Lilly and Company Medical Equipment Company Share Analysis" company...0400000004018000040020000400200604016000040160130401600504016001040160480401604707000000070030000700300107014000070140120200000002002000020020069/15/2008 11:20:55 AM180000001801500018020000180160001800800018012000Business WireBW-0001-28071728LILLY ELI & COLLYNewsNewstex